Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Avatrombopag is a non-peptide agonist of the thrombopoietin receptor that causes an increase in platelet production. Indicated for the treatment of severe thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures and for the treatment of chronic primary immune thrombocytopenia that does not respond to other treatments. Oral administration.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (very high volume of distribution and percentage of plasma protein binding, and moderately high molecular weight) make it very unlikely that it will pass into breast milk in clinically significant amounts.